Disease models are essential for understanding cardiovascular disease pathogenesis and
developing new therapeutics. The human induced pluripotent stem cell (iPSC) technology …

Cardiovascular diseases (CVD) constitute a major fraction of the current major global
diseases and lead to about 30% of the deaths, ie, 17.9 million deaths per year. CVD include …

Background: Advancing structural and functional maturation of stem cell–derived
cardiomyocytes remains a key challenge for applications in disease modeling, drug …

Despite increased use of human induced pluripotent stem cell-derived cardiomyocytes
(hiPSC-CMs) for drug development and disease modeling studies, methods to generate …

Background: Tissue engineering enables the generation of functional human cardiac tissue
with cells derived in vitro in combination with biocompatible materials. Human-induced …

Bioengineering of a functional cardiac tissue composed of primary cardiomyocytes has great
potential for myocardial regeneration and in vitro tissue modeling. However, its applications …

Since the advent of the generation of human induced pluripotent stem cells (hiPSCs),
numerous protocols have been developed to differentiate hiPSCs into cardiomyocytes and …

Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) provide a promising
source for cell therapy and drug screening. Several high-yield protocols exist for hESC-CM …

Cardiomyocytes from human pluripotent stem cells (hPSCs-CMs) could revolutionise
biomedicine. Global burden of heart failure will soon reach USD $90 bn, while unexpected …

The engineering of 3-dimensional (3D) heart muscles has undergone exciting progress for
the past decade. Profound advances in human stem cell biology and technology, tissue …